With a market capitalization (market cap) of $6.15B — a measure of how much the company is worth — Mirum Pharmaceuticals, Inc. is the 1269th most valuable company in Healthcare as of August 18, 2026. Shares trade at $100.87, up +1.04% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Visit websiteAs of August 18, 2026, Mirum Pharmaceuticals, Inc. (MIRM) is worth $6.15B — this is its market capitalization, the total value of all its outstanding shares.
Mirum Pharmaceuticals, Inc.’s market cap is $6.15B, which ranks it #1269 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Mirum Pharmaceuticals, Inc. (MIRM) shares trade at $100.87, up 1.04% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025